Doxorubicin and imatinib co-loaded pegylated nanostructured carriers to effectively overcome doxorubicin resistance in metastatic tumors

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: YONG, Chul Soon (Yeungnam University, Gyeongsan-Si, Korea, Republic Of)
  • Co-author(s): Jae Hee Kim: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
    Biki Gupta: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
    Shiva Pathak: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
    Raj Kumar Thapa: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
    Jee-Heon Jeong: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
    Dong Shik Kim: Hanyang University, Ansan-si, Korea, Republic Of
    Han-Gon Choi: Hanyang University, Ansan-si, Korea, Republic Of
    Chul Soon Yong: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
    Jong Oh Kim: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
  • Abstract:

    Methods

    We prepared PEGylated nanostructured platforms comprising a hybrid lipid core co-loaded with DOX and IMT(DOX/IMT-N). We evaluated in vitro cytotoxicity in MDA-MB-231 cells and in vivo anticancer effect on MDA-MB-231 xenograft model, comparing DOX/IMT-N to DOX monotherapy, DOX/IMT and DOX-N. In vitro cytotoxicity was additionally evaluated..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login